743 related articles for article (PubMed ID: 33588146)
21. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Ito T; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
24. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P
Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of [
Choi SJ; Choi SH; Lee DY; Lee JS; Kim DW; Jang JK
Eur Radiol; 2022 Jul; 32(7):4628-4637. PubMed ID: 35092473
[TBL] [Abstract][Full Text] [Related]
26. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
[TBL] [Abstract][Full Text] [Related]
27. Nuclear Imaging of Neuroendocrine Tumors.
Pollard J; McNeely P; Menda Y
Surg Oncol Clin N Am; 2020 Apr; 29(2):209-221. PubMed ID: 32151356
[TBL] [Abstract][Full Text] [Related]
28. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.
Waseem N; Aparici CM; Kunz PL
J Nucl Med; 2019 Jul; 60(7):882-891. PubMed ID: 30850504
[TBL] [Abstract][Full Text] [Related]
30. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
32. Impact of
Tan TH; Boey CY; Lee BN
Nucl Med Mol Imaging; 2018 Apr; 52(2):119-124. PubMed ID: 29662560
[TBL] [Abstract][Full Text] [Related]
33. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
34. The Impact of
Cuthbertson DJ; Barriuso J; Lamarca A; Manoharan P; Westwood T; Jaffa M; Fenwick SW; Nuttall C; Lalloo F; Prachalias A; Pizanias M; Wieshmann H; McNamara MG; Hubner R; Srirajaskanthan R; Vivian G; Ramage J; Weickert MO; Pritchard DM; Vinjamuri S; Valle J; Yip VS
Front Endocrinol (Lausanne); 2021; 12():654975. PubMed ID: 34163434
[TBL] [Abstract][Full Text] [Related]
35. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
36. Added value of [
Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
[TBL] [Abstract][Full Text] [Related]
37. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
38. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.
Ambrosini V; Zanoni L; Filice A; Lamberti G; Argalia G; Fortunati E; Campana D; Versari A; Fanti S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205805
[TBL] [Abstract][Full Text] [Related]
39. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
40. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]